Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2022.Dec.19

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP505, to US FDA

2022.Dec.09

Announcement on behalf of AP Biosciences that it obtains the Internal Control Special Audit Report by CPA

2022.Nov.28

Amendments to related matters that OBI forfeits part of subscription rights of Obigen’s cash capital increase and distributes the rights to its shareholders

2022.Nov.24

OBI sets target date of distribution of other benefits from forfeiture of subscription rights to its shareholders for Obigen’s 2022 cash capital increase

2022.Nov.24

The Company’s BOD resolved to forfeit part of subscription rights of Obigen’s cash capital increase and distribute the rights to its shareholders

2022.Nov.23

The Company correct the information on monetary loans extended to others filed on September and October 2022

2022.Nov.14

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by TFDA

2022.Nov.09

Announcement on behalf of APBio’s resolution to lift non-competition restrictions for directors at 2022 extraordinary Shareholders' Meeting

2022.Nov.09

Announcement on behalf of AP Biosciences. regarding its by-election of director and supervisor at 2022 first extraordinary General Shareholders' Meeting

2022.Nov.09

Announcement on behalf of AP Biosciences’ important resolutions of 2022 first extraordinary General Shareholders' Meeting

News

Latest News

Events

Latest events